Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Verheyen, N; Pilz, S; Eller, K; Kienreich, K; Fahrleitner-Pammer, A; Pieske, B; Ritz, E; Tomaschitz, A.
Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
Expert Opin Pharmacother. 2013; 14(6):793-806
Doi: 10.1517/14656566.2013.777041
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Tomaschitz Andreas
- Verheyen Nicolas Dominik
- Co-Autor*innen der Med Uni Graz
- Eller Kathrin
- Fahrleitner-Pammer Astrid
- Kienreich Katharina
- Pieske Burkert Mathias
- Pilz Stefan
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Effective therapeutic strategies are warranted to reduce the burden of parathyroid hormone excess related morbidity and mortality. The calcimimetic agent cinacalcet hydrochloride is a promising treatment strategy in hyperparathyroidism. This review provides an overview of the pharmacokinetics, clinical efficacy, cost-effectiveness, safety and the efficacy profile of cinacalcet in the setting of primary and secondary hyperparathyroidism (p/sHPT). The authors searched PubMed database for English language articles related to cinacalcet in human subjects, published till Dec 2012 - focusing on the period between 2008 and 2012. The use of cinacalcet in pHPT can be considered on those hypercalcemic patients in whom parathyroidectomy is not performed. However, data on the impact of cinacalcet on hard clinical outcomes in pHPT are missing. Despite effective improvements of biochemical parameters of sHPT, the intention-to-treat-based analysis of the EVOLVE trial did not support the notion that cinacalcet significantly reduces the risk of death or major cardiovascular events in dialysis patients with moderate-to-severe sHPT. Considering the strong evidence indicating beneficial effects of cinacalcet in the setting of HPT, further randomized controlled trials are definitely warranted to evaluate whether calcimimetic treatment might improve mortality and cardiovascular risk in patients with parathyroid hormone excess over a broad spectrum of kidney function.
- Find related publications in this database (using NLM MeSH Indexing)
- Calcimimetic Agents - adverse effects Calcimimetic Agents - economics Calcimimetic Agents - therapeutic use
- Cinacalcet Hydrochloride -
- Cost-Benefit Analysis -
- Humans -
- Hyperparathyroidism - drug therapy Hyperparathyroidism - etiology Hyperparathyroidism - physiopathology
- Kidney Diseases - complications Kidney Diseases - physiopathology
- Naphthalenes - adverse effects Naphthalenes - economics Naphthalenes - therapeutic use
- Parathyroid Hormone - blood
- Severity of Illness Index -
- Find related publications in this database (Keywords)
- calcimimetics
- calcium
- calcium-sensing receptor
- chronic kidney disease
- cinacalcet
- end-stage renal disease
- hypercalcemia
- parathyroid carcinoma
- parathyroid hormone
- primary hyperparathyroidism
- secondary hyperparathyroidism